GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » EV-to-EBITDA

10x Genomics (10x Genomics) EV-to-EBITDA : -14.56 (As of Apr. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is 10x Genomics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, 10x Genomics's enterprise value is $2,986.1 Mil. 10x Genomics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-205.1 Mil. Therefore, 10x Genomics's EV-to-EBITDA for today is -14.56.

The historical rank and industry rank for 10x Genomics's EV-to-EBITDA or its related term are showing as below:

TXG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -657.25   Med: -41.24   Max: -11.36
Current: -14.56

During the past 7 years, the highest EV-to-EBITDA of 10x Genomics was -11.36. The lowest was -657.25. And the median was -41.24.

TXG's EV-to-EBITDA is ranked worse than
100% of 460 companies
in the Healthcare Providers & Services industry
Industry Median: 13.195 vs TXG: -14.56

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), 10x Genomics's stock price is $26.90. 10x Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.170. Therefore, 10x Genomics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


10x Genomics EV-to-EBITDA Historical Data

The historical data trend for 10x Genomics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics EV-to-EBITDA Chart

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -332.44 -28.73 -660.90 -30.06 -31.06

10x Genomics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.06 -45.36 -48.33 -25.93 -31.06

Competitive Comparison of 10x Genomics's EV-to-EBITDA

For the Health Information Services subindustry, 10x Genomics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


10x Genomics's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where 10x Genomics's EV-to-EBITDA falls into.



10x Genomics EV-to-EBITDA Calculation

10x Genomics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2986.138/-205.111
=-14.56

10x Genomics's current Enterprise Value is $2,986.1 Mil.
10x Genomics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-205.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


10x Genomics  (NAS:TXG) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

10x Genomics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=26.90/-2.170
=At Loss

10x Genomics's share price for today is $26.90.
10x Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.170.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


10x Genomics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of 10x Genomics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


10x Genomics (10x Genomics) Business Description

Traded in Other Exchanges
Address
6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Executives
Serge Saxonov director, 10 percent owner, officer: Chief Executive Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
James Wilbur officer: Chief Commercial Officer C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588-3260
Benjamin J. Hindson director, officer: See Remarks 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Justin J. Mcanear officer: Chief Financial Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
John R Stuelpnagel director 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Mathai Mammen director THERAVANCE,INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Bradford Crutchfield officer: Chief Commercial Officer 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94547
Sridhar Kosaraju director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Venrock Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Associates Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Foresite Capital Fund I, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Paladin Capital Management, Llc 10 percent owner 2020 K STREET, NW, SUITE 620, WASHINGTON DC 20006